Brainstorm Cell Therapeutics reported $-5360000 in Net Income for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Biogen BIIB:US $ 303.8M 64.4M
Brainstorm Cell Therapeutics BCLI:US $ -5.36M 0.83M
Cerulean Pharma CERU:US $ -8.4M 1.14M
Cytokinetics CYTK:US $ -89.44M 58.88M
Gilead Sciences GILD:US $ 19M 363M
Halozyme Therapeutics HALO:US $ 60.11M 6.66M
Idera Pharmaceuticals IDRA:US $ -4.18M 0.06M